Overview

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
Phase:
Phase 2
Details
Lead Sponsor:
Hoechst Marion Roussel
Treatments:
Zidovudine